Verastem Stock Price, News & Analysis (NASDAQ:VSTM)

$3.65 -0.15 (-3.95 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$3.80
Today's Range$3.61 - $3.79
52-Week Range$1.08 - $5.71
Volume1.06 million shs
Average Volume801,066 shs
Market Capitalization$153.86 million
P/E RatioN/A
Dividend YieldN/A
Beta2.16

About Verastem (NASDAQ:VSTM)

Verastem logoVerastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:VSTM
CUSIP92337C10
Phone781-292-4200

Debt

Debt-to-Equity Ratio0.06%
Current Ratio3.12%
Quick Ratio3.12%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.95 per share
Price / Book1.87

Profitability

Trailing EPS($1.64)
Net Income$-36,440,000.00
Net MarginsN/A
Return on Equity-110.32%
Return on Assets-85.98%

Miscellaneous

Employees32
Outstanding Shares40,490,000

Verastem (NASDAQ:VSTM) Frequently Asked Questions

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) posted its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.29. View Verastem's Earnings History.

Where is Verastem's stock going? Where will Verastem's stock price be in 2017?

8 brokerages have issued 1 year target prices for Verastem's shares. Their forecasts range from $1.50 to $17.00. On average, they anticipate Verastem's share price to reach $10.93 in the next year. View Analyst Ratings for Verastem.

What are Wall Street analysts saying about Verastem stock?

Here are some recent quotes from research analysts about Verastem stock:

  • 1. Cann analysts commented, "Verastem presented the DUO data at the American Society of Hematology (ASH) 2017 on Sunday, December 10, 2017. Investigators concluded that DUO results support duvelisib oral monotherapy as a potential new and convenient treatment option for previously treated CLL/SLL patients and the adverse event profile of duvelisib was manageable. Based on the balance of efficacy and adverse events reported from the DUO study, we continue to expect that Verastem will launch duvelisib in 2019, and it will be the primary revenue and earnings driver for Verastem. Our outlook for duvelisib remains unchanged and positive. We are raising our target price to $15 from our prior target of $6 to reflect decreased risk of failure, now that details of the DUO data are released." (12/10/2017)
  • 2. According to Zacks Investment Research, "Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. " (11/8/2017)
  • 3. Cantor Fitzgerald analysts commented, "VSTM has made a $6 million milestone payment to INFI (Not Covered), following positive Phase III DUO results in September, with a final milestone of $22 million due upon regulatory approval, which could come in 2019 following a 2018 NDA filing." (10/17/2017)

Who are some of Verastem's key competitors?

Who are Verastem's key executives?

Verastem's management team includes the folowing people:

  • Robert Forrester, President, Chief Executive Officer (Age 52)
  • Julie B. Feder, Chief Financial Officer (Age 47)
  • Daniel W. Paterson, Chief Operating Officer (Age 53)
  • Joseph Chiapponi, Vice President - Finance (Age 48)
  • Monica Kleinman, Vice President, General Counsel (Age 34)
  • Michael Ferraresso, Vice President - Commercial Operations
  • Lori A. Kunkel M.D., Clinical and Scientific Advisory Board (Age 59)
  • Hagop Youssoufian M.Sc., M.D.,, Head - Hematology and Oncology Development (Age 59)
  • Michael G. Kauffman M.D. Ph.D., Lead Independent Director (Age 53)
  • Eric K. Rowinsky M.D., Director (Age 60)

Who owns Verastem stock?

Verastem's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (3.46%), Artal Group S.A. (2.03%), Dimensional Fund Advisors LP (1.39%), EAM Investors LLC (1.20%), ClariVest Asset Management LLC (0.24%) and Susquehanna International Group LLP (0.19%). Company insiders that own Verastem stock include Michael Kauffman and Timothy J Barberich. View Institutional Ownership Trends for Verastem.

Who bought Verastem stock? Who is buying Verastem stock?

Verastem's stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., EAM Investors LLC, Dimensional Fund Advisors LP, Artal Group S.A., ClariVest Asset Management LLC, Susquehanna International Group LLP, Citadel Advisors LLC and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Verastem.

How do I buy Verastem stock?

Shares of Verastem can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Verastem's stock price today?

One share of Verastem stock can currently be purchased for approximately $3.65.

How big of a company is Verastem?

Verastem has a market capitalization of $153.86 million. The biopharmaceutical company earns $-36,440,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Verastem employs 32 workers across the globe.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]


MarketBeat Community Rating for Verastem (VSTM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  237 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  379
MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Verastem (NASDAQ:VSTM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.832.832.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.93$7.75$5.25$4.00
Price Target Upside: 193.78% upside134.85% upside6.71% upside88.68% upside

Verastem (NASDAQ:VSTM) Consensus Price Target History

Price Target History for Verastem (NASDAQ:VSTM)

Verastem (NASDAQ:VSTM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/13/2017HC WainwrightSet Price TargetBuy$10.00MediumView Rating Details
12/11/2017Raymond James FinancialReiterated RatingBuyHighView Rating Details
12/10/2017OppenheimerReiterated RatingBuy$15.00HighView Rating Details
12/10/2017Cantor FitzgeraldSet Price TargetBuy$17.00HighView Rating Details
12/10/2017CannReiterated RatingBuy$6.00 -> $15.00HighView Rating Details
12/1/2017Roth CapitalInitiated CoverageBuy$12.00HighView Rating Details
6/28/2017Jefferies GroupReiterated RatingHold$1.50HighView Rating Details
4/13/2017CIBCReiterated RatingOutperform -> Outperform$6.00HighView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Verastem (NASDAQ:VSTM) Earnings History and Estimates Chart

Earnings by Quarter for Verastem (NASDAQ:VSTM)

Verastem (NASDAQ VSTM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.32)($0.61)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.34)($0.36)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.35)($0.35)ViewN/AView Earnings Details
11/7/2016Q3($0.24)($0.21)ViewN/AView Earnings Details
8/8/2016Q2($0.29)($0.23)ViewN/AView Earnings Details
5/9/2016($0.30)($0.22)ViewN/AView Earnings Details
3/3/2016Q415($0.36)($0.32)ViewListenView Earnings Details
8/10/2015Q2($0.45)($0.42)ViewN/AView Earnings Details
5/11/2015Q1($0.41)($0.46)ViewN/AView Earnings Details
3/10/2015($0.54)($0.53)ViewN/AView Earnings Details
10/30/2014($0.51)($0.52)ViewN/AView Earnings Details
5/8/2014($0.43)($0.51)ViewN/AView Earnings Details
3/6/2014Q4($0.47)($0.45)ViewListenView Earnings Details
11/12/2013Q3($0.44)($0.47)ViewN/AView Earnings Details
8/13/2013Q2 2013($0.41)($0.49)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.43)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Verastem (NASDAQ:VSTM) Earnings Estimates

2017 EPS Consensus Estimate: ($1.49)
2018 EPS Consensus Estimate: ($2.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.37)($0.37)($0.37)
Q2 20171($0.36)($0.36)($0.36)
Q3 20171($0.35)($0.35)($0.35)
Q4 20171($0.41)($0.41)($0.41)
Q1 20181($0.47)($0.47)($0.47)
Q2 20181($0.47)($0.47)($0.47)
Q3 20181($0.52)($0.52)($0.52)
Q4 20181($0.54)($0.54)($0.54)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Verastem (NASDAQ:VSTM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Verastem (NASDAQ VSTM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.51%
Institutional Ownership Percentage: 34.24%
Insider Trades by Quarter for Verastem (NASDAQ:VSTM)
Institutional Ownership by Quarter for Verastem (NASDAQ:VSTM)

Verastem (NASDAQ VSTM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/5/2017Timothy J BarberichDirectorBuy60,538$3.95$239,125.10View SEC Filing  
5/15/2017Timothy J BarberichDirectorBuy30,000$2.45$73,500.00View SEC Filing  
6/29/2015Monica SinghGeneral CounselBuy1,000$6.95$6,950.00View SEC Filing  
6/29/2015Robert ForresterCEOBuy2,000$7.11$14,220.00View SEC Filing  
6/18/2015Dan PatersonCOOBuy1,000$8.05$8,050.00View SEC Filing  
6/17/2015Robert ForresterCEOBuy1,000$7.97$7,970.00View SEC Filing  
1/28/2015Christoph H WestphalChairmanBuy1,230,769$6.50$7,999,998.50View SEC Filing  
1/28/2015Timothy J BarberichDirectorBuy38,462$6.50$250,003.00View SEC Filing  
12/29/2014Joanna HorobinInsiderBuy750$8.60$6,450.00View SEC Filing  
12/29/2014S. Louise PhanstielDirectorBuy10,000$8.54$85,400.00View SEC Filing  
12/26/2014Stephen A SherwinDirectorBuy2,500$8.56$21,400.00View SEC Filing  
12/24/2014Paul A FriedmanDirectorBuy3,000$8.31$24,930.00View SEC Filing  
12/23/2014Henri A TermeerDirectorBuy19,100$8.09$154,519.00View SEC Filing  
12/23/2014Monica SinghGeneral CounselBuy1,000$8.09$8,090.00View SEC Filing  
12/19/2014Christoph H WestphalChairmanBuy1,500$8.50$12,750.00View SEC Filing  
12/19/2014Dan PatersonCOOBuy2,000$8.52$17,040.00View SEC Filing  
12/19/2014Robert ForresterCEOBuy1,000$8.66$8,660.00View SEC Filing  
11/11/2014Alison Frances LawtonDirectorBuy2,500$9.17$22,925.00View SEC Filing  
9/17/2014Michael KauffmanDirectorBuy3,000$9.10$27,300.00View SEC Filing  
5/30/2014Timothy J BarberichDirectorBuy1,000$9.90$9,900.00View SEC Filing  
5/20/2014Richard AldrichDirectorBuy1,000$8.37$8,370.00View SEC Filing  
5/15/2014Dan PatersonInsiderBuy1,000$7.47$7,470.00View SEC Filing  
5/14/2014Christoph WestphalChairmanBuy2,000$7.56$15,120.00View SEC Filing  
5/13/2014Robert ForresterCEOBuy1,000$7.62$7,620.00View SEC Filing  
11/18/2013Christoph WestphalDirectorBuy1,000$9.60$9,600.00View SEC Filing  
11/11/2013Richard AldrichDirectorBuy1,000$10.93$10,930.00View SEC Filing  
11/4/2013Richard AldrichDirectorBuy1,000$10.51$10,510.00View SEC Filing  
10/28/2013Richard AldrichDirectorBuy1,000$11.26$11,260.00View SEC Filing  
10/21/2013Richard AldrichDirectorBuy1,000$12.57$12,570.00View SEC Filing  
10/14/2013Richard AldrichDirectorBuy1,000$10.56$10,560.00View SEC Filing  
10/7/2013Richard AldrichDirectorBuy1,000$11.53$11,530.00View SEC Filing  
9/30/2013Richard AldrichDirectorBuy1,000$12.55$12,550.00View SEC Filing  
9/23/2013Richard AldrichDirectorBuy1,000$13.17$13,170.00View SEC Filing  
9/16/2013Richard AldrichDirectorBuy1,000$13.81$13,810.00View SEC Filing  
9/9/2013Richard AldrichDirectorBuy1,000$14.04$14,040.00View SEC Filing  
9/3/2013Richard AldrichDirectorBuy1,000$14.07$14,070.00View SEC Filing  
8/26/2013Richard AldrichDirectorBuy1,000$14.21$14,210.00View SEC Filing  
8/19/2013Richard AldrichDirectorBuy1,000$13.45$13,450.00View SEC Filing  
8/12/2013Richard AldrichDirectorBuy1,000$14.75$14,750.00View SEC Filing  
8/5/2013Richard AldrichDirectorBuy1,000$15.25$15,250.00View SEC Filing  
7/29/2013Richard AldrichDirectorBuy1,000$15.15$15,150.00View SEC Filing  
7/24/2013Richard AldrichDirectorBuy1,000$16.39$16,390.00View SEC Filing  
7/15/2013Richard AldrichDirectorBuy1,000$17.19$17,190.00View SEC Filing  
7/8/2013Richard AldrichDirectorBuy1,000$14.69$14,690.00View SEC Filing  
7/1/2013Richard AldrichDirectorBuy1,000$14.11$14,110.00View SEC Filing  
6/13/2013Robert ForresterCOOBuy1,000$11.39$11,390.00View SEC Filing  
6/12/2013Henri A TermeerDirectorBuy5,823$9.74$56,716.02View SEC Filing  
6/12/2013Lp Chp IIIMajor ShareholderBuy48,171$9.40$452,807.40View SEC Filing  
6/11/2013S. Louise PhanstielDirectorBuy12,000$9.30$111,600.00View SEC Filing  
6/7/2013Christoph H WestphalCEOBuy1,000$9.06$9,060.00View SEC Filing  
5/13/2013John K ClarkeDirectorBuy25,000$9.74$243,500.00View SEC Filing  
5/1/2013John K ClarkeDirectorBuy10,000$9.66$96,600.00View SEC Filing  
4/17/2013John K ClarkeDirectorBuy5,631$9.50$53,494.50View SEC Filing  
12/18/2012Lp Chp IIIMajor ShareholderBuy6,193$7.87$48,738.91View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Verastem (NASDAQ VSTM) News Headlines

Source:
DateHeadline
Verastem Announces Public Offering of Common StockVerastem Announces Public Offering of Common Stock
finance.yahoo.com - December 15 at 11:02 AM
Verastem Announces Pricing of Public Offering of Common StockVerastem Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - December 15 at 11:02 AM
3 Stocks to Watch on Friday: DDR Corp (DDR), Hess Corp. (HES) and Verastem Inc (VSTM)3 Stocks to Watch on Friday: DDR Corp (DDR), Hess Corp. (HES) and Verastem Inc (VSTM)
investorplace.com - December 15 at 8:36 AM
Verastem: Revisiting This Small Biotech Name After ASH - Seeking AlphaVerastem: Revisiting This Small Biotech Name After ASH - Seeking Alpha
seekingalpha.com - December 14 at 10:43 AM
Verastem Jumps on Leukemia Drug Study Results - Investopedia (blog)Verastem Jumps on Leukemia Drug Study Results - Investopedia (blog)
www.investopedia.com - December 13 at 10:56 AM
Verastem (VSTM) Reports Clinical Data from the Pivotal Phase 3 DUO - StreetInsider.comVerastem (VSTM) Reports Clinical Data from the Pivotal Phase 3 DUO - StreetInsider.com
www.streetinsider.com - December 13 at 10:56 AM
Verastem (VSTM) Given a $10.00 Price Target at HC WainwrightVerastem (VSTM) Given a $10.00 Price Target at HC Wainwright
www.americanbankingnews.com - December 13 at 9:18 AM
Today’s Research Reports on Trending Tickers: Array BioPharma and Verastem, Inc.Today’s Research Reports on Trending Tickers: Array BioPharma and Verastem, Inc.
finance.yahoo.com - December 12 at 11:01 AM
Cantor Fitzgerald Analysts Give Verastem (VSTM) a $17.00 Price TargetCantor Fitzgerald Analysts Give Verastem (VSTM) a $17.00 Price Target
www.americanbankingnews.com - December 11 at 10:10 PM
Verastems (VSTM) Buy Rating Reiterated at Raymond James FinancialVerastem's (VSTM) Buy Rating Reiterated at Raymond James Financial
www.americanbankingnews.com - December 11 at 5:08 PM
2 Biotech Stocks to Have On Your Radar Into the New Year2 Biotech Stocks to Have On Your Radar Into the New Year
finance.yahoo.com - December 11 at 4:31 PM
Verastems (VSTM) "Buy" Rating Reiterated at OppenheimerVerastem's (VSTM) "Buy" Rating Reiterated at Oppenheimer
www.americanbankingnews.com - December 11 at 1:26 PM
Verastem Announces Clinical Data from the Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaVerastem Announces Clinical Data from the Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
finance.yahoo.com - December 11 at 11:17 AM
Verastem Jumps on Leukemia Drug Study ResultsVerastem Jumps on Leukemia Drug Study Results
finance.yahoo.com - December 11 at 11:17 AM
Verastem (VSTM) Stock Rating Reaffirmed by CannVerastem (VSTM) Stock Rating Reaffirmed by Cann
www.americanbankingnews.com - December 11 at 12:52 AM
Verastem Announces Clinical Data from the Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves ... - Business Wire (press release)Verastem Announces Clinical Data from the Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves ... - Business Wire (press release)
www.businesswire.com - December 10 at 4:32 PM
Timothy J. Barberich Purchases 60,538 Shares of Verastem, Inc. (VSTM) StockTimothy J. Barberich Purchases 60,538 Shares of Verastem, Inc. (VSTM) Stock
www.americanbankingnews.com - December 7 at 5:56 PM
Verastem to Present Results from Pivotal Phase 3 DUO Study in ... - Business Wire (press release)Verastem to Present Results from Pivotal Phase 3 DUO Study in ... - Business Wire (press release)
www.businesswire.com - December 7 at 4:37 PM
Verastem to Present Results from Pivotal Phase 3 DUO Study in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at a Research and Development Event at ASH 2017Verastem to Present Results from Pivotal Phase 3 DUO Study in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at a Research and Development Event at ASH 2017
finance.yahoo.com - December 5 at 12:18 PM
Verastem (VSTM) Cut to "Strong Sell" at ValuEngineVerastem (VSTM) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - December 1 at 11:52 PM
Verastem (VSTM) Earns Buy Rating from Analysts at Roth CapitalVerastem (VSTM) Earns Buy Rating from Analysts at Roth Capital
www.americanbankingnews.com - December 1 at 7:38 PM
30 Stocks Moving In Thursdays Mid-Day Session30 Stocks Moving In Thursday's Mid-Day Session
feeds.benzinga.com - November 30 at 1:44 PM
Pre-Open Movers 11/30: (SHLD) (SNPS) (ADMP) Higher; (BKS) (JNPR) (SMTC+) Lower (more...)Pre-Open Movers 11/30: (SHLD) (SNPS) (ADMP) Higher; (BKS) (JNPR) (SMTC+) Lower (more...)
www.streetinsider.com - November 30 at 11:14 AM
Verastem, Inc. (VSTM) Receives Average Rating of "Buy" from BrokeragesVerastem, Inc. (VSTM) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 27 at 5:56 AM
Options Traders Expect Huge Moves in Verastem (VSTM) Stock - NasdaqOptions Traders Expect Huge Moves in Verastem (VSTM) Stock - Nasdaq
www.nasdaq.com - November 20 at 12:09 PM
Options Traders Expect Huge Moves in Verastem (VSTM) StockOptions Traders Expect Huge Moves in Verastem (VSTM) Stock
finance.yahoo.com - November 20 at 12:09 PM
FY2017 EPS Estimates for Verastem, Inc. (VSTM) Lowered by Oppenheimer HoldingsFY2017 EPS Estimates for Verastem, Inc. (VSTM) Lowered by Oppenheimer Holdings
www.americanbankingnews.com - November 10 at 12:38 PM
Verastem to Present at Upcoming Investor ConferencesVerastem to Present at Upcoming Investor Conferences
finance.yahoo.com - November 9 at 9:41 AM
Verastem, Inc. (VSTM) Rating Reiterated by HC WainwrightVerastem, Inc. (VSTM) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - November 8 at 10:26 PM
Verastem, Inc. (VSTM) Posts Quarterly  Earnings Results, Misses Expectations By $0.29 EPSVerastem, Inc. (VSTM) Posts Quarterly Earnings Results, Misses Expectations By $0.29 EPS
www.americanbankingnews.com - November 8 at 4:23 PM
Verastem, Inc. (VSTM) Stock Rating Upgraded by Zacks Investment ResearchVerastem, Inc. (VSTM) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 8 at 2:54 PM
Verastem Reports Third Quarter 2017 Financial Results | Business ... - Business Wire (press release)Verastem Reports Third Quarter 2017 Financial Results | Business ... - Business Wire (press release)
www.businesswire.com - November 8 at 4:28 AM
Verastems (VSTM) "Buy" Rating Reiterated at CannVerastem's (VSTM) "Buy" Rating Reiterated at Cann
www.americanbankingnews.com - November 7 at 3:52 PM
Verastem Reports Third Quarter 2017 Financial ResultsVerastem Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 1:19 PM
Verastem reports 3Q lossVerastem reports 3Q loss
finance.yahoo.com - November 7 at 1:19 PM
Verastem (VSTM) Announces Data from Phase 3 DUO Study Selected for Oral Presentation at ASHVerastem (VSTM) Announces Data from Phase 3 DUO Study Selected for Oral Presentation at ASH
www.streetinsider.com - November 2 at 9:10 PM
Corporate News Blog - Verastem Announces Plans to Submit NDA Requesting Full Approval of Duvelisib for Treatment of Patients with Relapsed or Refractory CLL/SLLCorporate News Blog - Verastem Announces Plans to Submit NDA Requesting Full Approval of Duvelisib for Treatment of Patients with Relapsed or Refractory CLL/SLL
finance.yahoo.com - November 2 at 11:05 AM
Verastem, Inc. (VSTM) Given Average Recommendation of "Hold" by BrokeragesVerastem, Inc. (VSTM) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 2 at 5:28 AM
Verastem (VSTM) Provides Regulatory Strategy for Duvelisib NDA Following Guidance from FDA - StreetInsider.comVerastem (VSTM) Provides Regulatory Strategy for Duvelisib NDA Following Guidance from FDA - StreetInsider.com
www.streetinsider.com - November 1 at 10:35 AM
Verastem (VSTM) Announces Data from Phase 3 DUO Study Selected for Oral Presentation at ASH - StreetInsider.comVerastem (VSTM) Announces Data from Phase 3 DUO Study Selected for Oral Presentation at ASH - StreetInsider.com
www.streetinsider.com - November 1 at 10:35 AM
Verastem Announces Data from Phase 3 DUO Study Selected for Oral Presentation at the American Society of Hematology 2017 Annual MeetingVerastem Announces Data from Phase 3 DUO Study Selected for Oral Presentation at the American Society of Hematology 2017 Annual Meeting
finance.yahoo.com - November 1 at 10:35 AM
Verastem (VSTM) Provides Regulatory Strategy for Duvelisib NDA Following Guidance from FDAVerastem (VSTM) Provides Regulatory Strategy for Duvelisib NDA Following Guidance from FDA
www.streetinsider.com - October 31 at 11:54 AM
Verastem Announces Regulatory Strategy for Duvelisib New Drug Application Following Guidance from FDAVerastem Announces Regulatory Strategy for Duvelisib New Drug Application Following Guidance from FDA
finance.yahoo.com - October 31 at 11:54 AM
Cantor Fitzgerald Analysts Give Verastem, Inc. (VSTM) a $17.00 Price TargetCantor Fitzgerald Analysts Give Verastem, Inc. (VSTM) a $17.00 Price Target
www.americanbankingnews.com - October 31 at 10:08 AM
Verastem, Inc. (VSTM) Scheduled to Post Quarterly Earnings on MondayVerastem, Inc. (VSTM) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 9:36 AM
 Brokerages Anticipate Verastem, Inc. (VSTM) to Announce -$0.32 Earnings Per Share Brokerages Anticipate Verastem, Inc. (VSTM) to Announce -$0.32 Earnings Per Share
www.americanbankingnews.com - October 28 at 11:36 AM
Verastem Pays Milestone Payment to Infinity Pharmaceuticals - Business Wire (press release)Verastem Pays Milestone Payment to Infinity Pharmaceuticals - Business Wire (press release)
www.businesswire.com - October 17 at 8:56 AM
Verastem Pays Milestone Payment to Infinity PharmaceuticalsVerastem Pays Milestone Payment to Infinity Pharmaceuticals
finance.yahoo.com - October 17 at 8:56 AM
Verastem, Inc. (VSTM) Rating Reiterated by Oppenheimer Holdings, Inc.Verastem, Inc. (VSTM) Rating Reiterated by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - October 12 at 2:34 PM
Verastem Appoints NgocDiep Le, MD, PhD as Chief Medical OfficerVerastem Appoints NgocDiep Le, MD, PhD as Chief Medical Officer
finance.yahoo.com - October 12 at 10:00 AM

SEC Filings

Verastem (NASDAQ:VSTM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Verastem (NASDAQ:VSTM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Verastem (NASDAQ VSTM) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.